Related Experiment Video

Updated: Jun 11, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeted trials in ovarian cancer

Jonathan A Ledermann1, Fharat A Raja

  • 1UCL Cancer Institute, University College London, London W1T 4TJ, UK. j.ledermann@ctc.ucl.ac.uk

Gynecologic Oncology
|July 2, 2010
PubMed

Insights

Molecular targeted agents, especially anti-angiogenic therapies like bevacizumab, are expanding in ovarian cancer clinical trials. This review examines their rationale, current trials, and future use in treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Ovarian cancer treatment is evolving with molecular targeted agents.
  • Anti-angiogenic therapies represent a significant focus in recent clinical trials.

Purpose of the Study:

  • To review the rationale and current randomized trials of molecular targeted therapy in ovarian cancer.
  • To focus on anti-angiogenic agents, including bevacizumab and VEGFR inhibitors.
  • To discuss other targeted agents such as EGFR, α-folate receptor, PARP, src kinase, and IGFR inhibitors.

Main Methods:

  • Review of recent clinical trials in ovarian cancer.
  • Focus on anti-angiogenic agents and other molecularly targeted therapies.
  • Analysis of trial designs, including first-line and recurrent disease settings.

Main Results:

  • Major expansion in molecular targeted agent trials over the last five years.
  • Anti-angiogenic agents, particularly bevacizumab, are prominent.
  • Results from ongoing bevacizumab trials are anticipated soon, with more targeted therapy trial results to follow.

Conclusions:

  • Molecular targeted therapy, especially anti-angiogenic agents, shows promise in ovarian cancer.
  • Complex issues regarding sequencing, duration, and agent selection require further investigation.
  • Optimizing the use of molecular targeted agents is crucial for advancing ovarian cancer treatment.

More Related Videos

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...